Jetrea(ocriplasmin)
Jetrea (ocriplasmin) is an enzyme pharmaceutical. Ocriplasmin was first approved as Jetrea on 2012-10-17. It is used to treat retinal diseases in the USA. It has been approved in Europe to treat retinal diseases.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ocriplasmin
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Jetrea | ocriplasmin | Oxurion | N-125422 DISCN | 2012-10-17 | 2 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| retinal diseases | HP_0000479 | D012164 | H35.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J7316 | Injection, ocriplasmin, 0.125 mg |
Clinical
Clinical Trials
98 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | 4 | 3 | 3 | 3 | 13 | ||
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | 1 | 3 | 2 | 1 | 7 |
| Empyema | D004653 | EFO_0003097 | — | — | — | 1 | — | 1 | |
| Pleural diseases | D010995 | — | — | — | 1 | — | 1 | ||
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | 1 | — | 1 |
| Thrombectomy | D017131 | — | — | — | 1 | — | 1 | ||
| Subdural hematoma | D006408 | HP_0100309 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | 3 | 9 | 4 | — | 4 | 19 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 4 | — | — | 4 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | 1 | 2 | — | — | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 3 | — | — | 3 |
| Coronary disease | D003327 | — | — | 3 | — | — | 3 | ||
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 3 | — | — | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 3 | — | — | 3 |
| Pleural empyema | D016724 | J86 | — | — | 1 | — | — | 1 | |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | 1 | — | — | 1 |
| Postphlebitic syndrome | D011186 | I87.0 | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral intraventricular hemorrhage | D000074042 | — | 2 | — | — | 1 | 3 | ||
| Vitrectomy | D014821 | — | 3 | — | — | — | 3 | ||
| Macular edema | D008269 | — | 1 | — | — | 1 | 2 | ||
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 2 | — | — | — | 2 |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | 1 | 2 | |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 1 | 2 | — | — | — | 2 |
| Intracranial aneurysm | D002532 | EFO_0003870 | I67.1 | 1 | 1 | — | — | — | 1 |
| Intracranial vasospasm | D020301 | EFO_1000994 | G45.9 | 1 | 1 | — | — | — | 1 |
| Hydrocephalus | D006849 | HP_0000238 | G91 | 1 | 1 | — | — | — | 1 |
| Neoplasms | D009369 | C80 | 1 | 1 | — | — | — | 1 |
Show 7 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | 2 | — | — | — | — | 2 |
| Malignant pleural effusion | D016066 | J91.0 | 1 | — | — | — | — | 1 | |
| Thrombosis | D013927 | 1 | — | — | — | — | 1 | ||
| Embolism | D004617 | 1 | — | — | — | — | 1 | ||
| Thrombophlebitis | D013924 | HP_0004418 | 1 | — | — | — | — | 1 | |
| Peritoneal dialysis | D010530 | 1 | — | — | — | — | 1 | ||
| Continuous ambulatory peritoneal dialysis | D010531 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertensive intracranial hemorrhage | D020299 | — | — | — | — | 1 | 1 | ||
| Brain injuries | D001930 | S06.9 | — | — | — | — | 1 | 1 | |
| Rupture | D012421 | — | — | — | — | 1 | 1 | ||
| Abdominal abscess | D018784 | EFO_1001753 | — | — | — | — | 1 | 1 | |
| Mortality | D009026 | EFO_0004352 | — | — | — | — | 1 | 1 | |
| Abdominal pain | D015746 | R10.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OCRIPLASMIN |
| INN | ocriplasmin |
| Description | Ocriplasmin, sold under the brand name Jetrea, is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from the retina.
|
| Classification | Enzyme |
| Drug class | plasmin proteins and derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1048016-09-6 |
| RxCUI | 29998 |
| ChEMBL ID | CHEMBL2095222 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB08888 |
| UNII ID | 7V6HE3DM5A (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 384 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18,571 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more